Drug Type Small molecule drug |
Synonyms S-Farnesylthiosalicyclic acid, Salirasib (INN/USAN), Transfarnesylthiosalicyclic acid + [3] |
Target |
Action inhibitors |
Mechanism RAS inhibitors(RAS type GTPase family inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC22H30O2S |
InChIKeyWUILNKCFCLNXOK-CFBAGHHKSA-N |
CAS Registry162520-00-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | United States | 01 Sep 2007 | |
Non-Small Cell Lung Cancer | Phase 2 | - | - | |
Pancreatic Cancer | Phase 2 | - | - | |
Leukemia | Phase 1 | United States | 01 May 2006 | |
Myelodysplastic Syndromes | Phase 1 | United States | 01 May 2006 | |
Colorectal Cancer | Phase 1 | United States | - | |
Solid tumor | Phase 1 | Japan | - |
Phase 2 | 33 | vyudfkkuku(qnldibxxlf) = odlpokvwtk mqyrptzqwb (ndybgffaao ) View more | - | 20 May 2009 | |||
Phase 1 | 12 | ahyqzvocxu(tzxzvxcxbx) = wrbiwwoshl umpwuhwqwj (cbrblbftkr ) | Positive | 20 Jun 2007 |